Zentalis Pharmaceuticals Llc (ZNTL) - Net Assets
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has net assets worth $216.20 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($288.97 Million) and total liabilities ($72.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zentalis Pharmaceuticals Llc (ZNTL) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $216.20 Million |
| % of Total Assets | 74.82% |
| Annual Growth Rate | 31.2% |
| 5-Year Change | -40.68% |
| 10-Year Change | N/A |
| Growth Volatility | 137.96 |
Zentalis Pharmaceuticals Llc - Net Assets Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Zentalis Pharmaceuticals Llc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual net assets of Zentalis Pharmaceuticals Llc from 2018 to 2025. For live valuation and market cap data, see how much is Zentalis Pharmaceuticals Llc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $216.20 Million | -35.88% |
| 2024-12-31 | $337.19 Million | -22.91% |
| 2023-12-31 | $437.39 Million | +0.78% |
| 2022-12-31 | $434.02 Million | +19.08% |
| 2021-12-31 | $364.48 Million | +9.33% |
| 2020-12-31 | $333.38 Million | +387.24% |
| 2019-12-31 | $68.42 Million | +111.79% |
| 2018-12-31 | $32.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zentalis Pharmaceuticals Llc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 115412500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $69.00K | 0.03% |
| Other Comprehensive Income | $196.00K | 0.09% |
| Other Components | $1.41 Billion | 650.96% |
| Total Equity | $216.20 Million | 100.00% |
Zentalis Pharmaceuticals Llc Competitors by Market Cap
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Som Distilleries & Breweries Limited
NSE:SDBL
|
$195.95 Million |
|
Shinfox Energy Co Ltd
TW:6806
|
$195.98 Million |
|
Smec Co.Ltd
KQ:099440
|
$196.00 Million |
|
Petrus Resources Ltd
TO:PRQ
|
$196.02 Million |
|
TigerElec Co. Ltd
KQ:219130
|
$195.77 Million |
|
Arise Windpower AB
ST:ARISE
|
$195.75 Million |
|
Tribune Resources Ltd
AU:TBR
|
$195.65 Million |
|
InfuSystems Holdings Inc
NYSE MKT:INFU
|
$195.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zentalis Pharmaceuticals Llc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 337,186,000 to 216,204,000, a change of -120,982,000 (-35.9%).
- Net loss of 137,060,000 reduced equity.
- Share repurchases of 9,976,000 reduced equity.
- New share issuances of 5,694,000 increased equity.
- Other comprehensive income decreased equity by 361,999.
- Other factors increased equity by 20,721,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-137.06 Million | -63.39% |
| Share Repurchases | $9.98 Million | -4.61% |
| Share Issuances | $5.69 Million | +2.63% |
| Other Comprehensive Income | $-362.00K | -0.17% |
| Other Changes | $20.72 Million | +9.58% |
| Total Change | $- | -35.88% |
Book Value vs Market Value Analysis
This analysis compares Zentalis Pharmaceuticals Llc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.98x to 1.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.37 | $4.09 | x |
| 2019-12-31 | $1.72 | $4.09 | x |
| 2020-12-31 | $7.52 | $4.09 | x |
| 2021-12-31 | $8.53 | $4.09 | x |
| 2022-12-31 | $8.21 | $4.09 | x |
| 2023-12-31 | $6.69 | $4.09 | x |
| 2024-12-31 | $4.74 | $4.09 | x |
| 2025-12-31 | $3.01 | $4.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zentalis Pharmaceuticals Llc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.34x
- Recent ROE (-63.39%) is below the historical average (-59.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -85.05% | -150478.57% | 0.00x | 1.66x | $-23.54 Million |
| 2019 | -74.13% | 0.00% | 0.00x | 1.43x | $-51.82 Million |
| 2020 | -38.19% | 0.00% | 0.00x | 1.18x | $-148.70 Million |
| 2021 | -43.61% | 0.00% | 0.00x | 1.30x | $-195.12 Million |
| 2022 | -54.59% | 0.00% | 0.00x | 1.28x | $-280.19 Million |
| 2023 | -66.82% | 0.00% | 0.00x | 1.29x | $-335.92 Million |
| 2024 | -49.18% | -245.96% | 0.16x | 1.28x | $-199.56 Million |
| 2025 | -63.39% | 0.00% | 0.00x | 1.34x | $-158.68 Million |
Industry Comparison
This section compares Zentalis Pharmaceuticals Llc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zentalis Pharmaceuticals Llc (ZNTL) | $216.20 Million | -85.05% | 0.34x | $195.77 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more